

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

SCHEDULE 14A

**PROXY STATEMENT
PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to Section 240.14a-12

IBIO, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (check the appropriate box):

- No fee required.
 - Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies: _____
 - (2) Aggregate number of securities to which transaction applies: _____
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): _____
 - (4) Proposed maximum aggregate value of transaction: _____
 - (5) Total fee paid: _____
 - Fee paid previously with preliminary materials.
 - Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid: _____
 - (2) Form, Schedule or Registration Statement No.: _____
 - (3) Filing Party: _____
 - (4) Date Filed: _____
-

Explanatory Note

Commencing December 3, 2021, iBio, Inc. (“iBio”) will begin posting the communications set forth below (the “Communications”) on Facebook, Twitter and other social media and internet platforms. The Communications supplement the Definitive Proxy Statement filed by iBio with the U.S. Securities and Exchange Commission (the “SEC”) on October 26, 2021 and the Definitive Additional Materials filed by iBio with the SEC on October 26, 2021, November 9, 2021, November 16, 2021, November 17, 2021, November 24, 2021, and November 30, 2021.

Vote Reminder:

\$IBIO shareholders have you voted “FOR” all proposals in the proxy statement? We urge you to vote prior to 12/9 to support our growth plans. Your vote is important, no matter how many shares it represents. For assistance, email info@okapipartners.com



Vote Reminder:

\$IBIO shareholders vote “FOR” all proposals on the agenda prior to our Annual Meeting on 12/9 to help us realize our vision of changing the biologic drug manufacturing paradigm. For assistance voting, call 1-844-203-3605 (U.S./Canada), or +1-212-297-0720 (international)

